Business Wire

Carbios Announces the Publication of an Article on Its Enzymatic Recycling Technology in the Prestigious Scientific Journal Nature

Share

Regulatory News:

CARBIOS (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announces the publication of an article in the prestigious scientific journal Nature, entitled “ An engineered PET-depolymerase to break down and recycle plastic bottles”. The article is co-authored by scientists at Carbios and at the Company’s renowned academic partner, the Toulouse Biotechnology Institute 1 (TBI).

The article describes the development of a novel enzyme, which can biologically depolymerize all polyethylene terephthalate (PET) plastic waste, followed by an extremely efficient recycling into new bottles. PET is the most common thermoplastic polymer and is used to manufacture bottles, polyester clothing fibers, food containers, and various thermoformed packaging and components. Carbios’ recycling process, the first of its kind, initiates a real transition to a circular economy and can better prevent plastic pollution from harming our oceans and planet. This innovative technology also paves the way for recycling PET fibers, another major challenge in guaranteeing a clean and protected environment for future generations.

Prof. Alain Marty, Carbios’ Chief Scientific Officer and co-author of the Nature article says:"I am very proud that Nature, one of the most highly respected scientific journals in the world, has validated the quality of the research led by Carbios and TBI laboratory scientists in developing a PET recycling enzyme and a revolutionary process. The results obtained confirm the industrial and commercial potential of the Company’s proprietary process, which will be tested in 2021 in our demonstration plant in the heart of the French Chemical Valley, near Lyon."

Sophie Duquesne, INRAE Researcher:“For any researcher, seeing its work recognized by the prestigious journal Nature is a true achievement. I am very proud of the work accomplished by the researchers at TBI and Carbios, whose collaborative efforts have led to the development of a sustainable solution to the end of life of plastics.”

Dr. Saleh Jabarin, Distinguished Professor at The University of Toledo, Ohio and a member of Carbios’ Scientific Committee: “It's a real breakthrough in the recycling and manufacturing of PET. Thanks to the innovative technology developed by Carbios, the PET industry will become truly circular, which is the goal for all players in this industry, especially brand-owners, PET producers and our civilization as a whole.”

Bertrand Piccard, Founder and President of the Solar Impulse Foundation: “I am very pleased that the scientific community recognizes one of the solutions labelled by the Solar Impulse Foundation as a financially profitable solution to protect the environment. The use of such technology is as logical as it is ecological!”

Nature, the highest Impact Factor scientific journal, recognizes the ground-breaking quality of the enzymatic engineering research being done by Carbios and TBI, that is paving the way to virtuous management of plastic waste. “Carbios is the first company to successfully combine the two scientific worlds of enzymology and plastics”, as Dr. Philippe Pouletty, CEO of Truffle Capital and Co-founder of Carbios, comments.

By leveraging many years of experience with a world-renowned team, Carbios and TBI are proud to have been able to increase the degradation yield of PET waste to 90% in 10 hours, a significant upswing from the initial degradation yield of 1% after several weeks. This paradigm shift in how effectively PET can be recycled, is leading toward a future circular economy technology applicable to all PET waste, which Carbios is proud to be spearheading.

To read the article in Nature, please find the link here:

https://www.nature.com/articles/s41586-020-2149-4

About Carbios:

Carbios is a green chemistry company whose innovations help address the environmental and sustainable development challenges facing manufacturers. Since its creation in 2011 by Truffle Capital, the Company has developed, through biotechnology, two industrial processes that revolutionize the biodegradation and recycling of polymers. These world-first innovations, made possible with the support of Bpifrance (THANAPLAST™ project), enable to optimize the performance and lifecycle of plastics and textiles by exploiting the properties of highly specific enzymes.

Carbios' economic development model is based on the industrialization and commercialization of its products and/or enzymes, technologies and bioprocesses through license concessions directly or through joint ventures to major industrial players or sectors concerned by the Company's innovations. As such, Carbios created the joint venture Carbiolice in September 2016, in partnership with Limagrain Ingredients and the SPI fund operated by Bpifrance. This company, of which Carbios has majority control, will exploit the first technology licensed by Carbios by producing enzymatic granules for the production of biodegradable and biobased plastics.

Carbios benefits from the qualification "Innovative Company" of Bpifrance allowing the eligibility of the Company's securities for the investment of Mutual Funds Placement in Innovation (FCPI). For more information, please visit: www.carbios.fr

Carbios is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

About Truffle Capital:

Established in 2001, Truffle Capital is a leading European Venture Capital company, specializing in breakthrough life sciences and FinTech technologies. Truffle Capital supports the creation and growth of young innovative companies capable of becoming tomorrow’s leaders. Headed by Patrick Kron, chairman, alongside cofounders and co-CEOs Philippe Pouletty, MD, and Bernard-Louis Roques, Truffle Capital has raised over €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors.

For more information: www.truffle.com – Twitter: @trufflecapital

This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country.

Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail.

1 : A mixed research unit INSA Toulouse, INRAE, CNRS.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CARBIOS
Benjamin Audebert
Investor Relations
contact@carbios.fr
+33 (0)4 73 86 51 76

Media Relations (Europe)
Tilder
Marie-Virginie Klein
mv.klein@tilder.com
+33 (0)1 44 14 99 96

Media Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release

Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release

Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye